Phase I clinical trial dose escalation - 4th cohort

Sep 09, 2015EVENTSHit 904

The third cohort (100 mg) in dose escalation of Phase I clinical trial to evaluate the safety was finished successfully. The safety monitoring committee (SMC) recommended a dose escalation to the next level (140 mg). Three clinical sites in the USA started recruitment of patients with solid tumor for the forth cohort.

Previous Clinical trial of TEW-7197 starts its first step.
Next Stock issuance